VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE PDE4B INHIBITOR (SYH2059 POWDER FOR INHALATION) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

Contact Us

Products

• Core Product
• API
• Formulation
• Quality Assurance

Science

• R&D
• Solutions

About Us

• Who are we
• Our history
• Main production base
• Governance and Leadership